|
induced pluripotent stem cells |
13 |
|
animals |
9 |
|
cell differentiation - drug effects |
9 |
|
mice |
9 |
|
calcium - metabolism |
8 |
|
cardiac differentiation |
8 |
|
cardiomyocytes |
8 |
|
cardiomyopathy |
8 |
|
cell line |
8 |
|
cell movement - drug effects |
8 |
|
embryonic stem cell |
8 |
|
embryonic stem cells |
8 |
|
embryonic stem cells - cytology - drug effects - transplantation |
8 |
|
embryonic stem cells - cytology - metabolism |
8 |
|
ferric compounds - adverse effects |
8 |
|
green fluorescent proteins - analysis - biosynthesis |
8 |
|
hypoxia |
8 |
|
magnetic resonance imaging - methods |
8 |
|
myocytes, cardiac - cytology - drug effects |
8 |
|
nanoparticles - adverse effects |
8 |
|
staining and labeling - methods |
8 |
|
superparamagnetic iron oxide |
8 |
|
anoxia - metabolism |
7 |
|
antigens, differentiation - biosynthesis |
7 |
|
antimutagenic agents - pharmacology |
7 |
|
biology |
7 |
|
cell differentiation |
7 |
|
cells, cultured |
7 |
|
cobalt - pharmacology |
7 |
|
cytokines - biosynthesis |
7 |
|
embryonic stem cells - cytology |
7 |
|
heart - physiology |
7 |
|
homeostasis - drug effects |
7 |
|
humans |
7 |
|
hypoxia inducible factor-1α |
7 |
|
hypoxia-inducible factor 1, alpha subunit - biosynthesis |
7 |
|
models, biological |
7 |
|
myocardium - cytology - metabolism |
7 |
|
myocardium - metabolism |
7 |
|
organ specificity - drug effects |
7 |
|
rna, messenger - metabolism |
7 |
|
sarcoplasmic reticulum function |
7 |
|
signal transduction |
7 |
|
troponin t - biosynthesis |
7 |
|
up-regulation |
7 |
|
vascular endothelial growth factor a - metabolism |
7 |
|
aged |
6 |
|
apolipoprotein a-i - metabolism |
6 |
|
calcium handling |
6 |
|
deferiprone |
6 |
|
friedreich ataxia |
6 |
|
friedreich's ataxia |
6 |
|
homeostasis |
6 |
|
human induced pluripotent stem cells |
6 |
|
idebenone |
6 |
|
induced pluripotent stem cells - cytology |
6 |
|
myocytes, cardiac - cytology/drug effects - metabolism |
6 |
|
pluripotent stem cells - cytology |
6 |
|
atrial fibrillation |
5 |
|
atrial fibrillation - pathology - therapy |
5 |
|
autophagy |
5 |
|
calcium signaling |
5 |
|
dilated cardiomyopathy |
5 |
|
electric countershock |
5 |
|
electrical cardioversion |
5 |
|
electrical stimulation |
5 |
|
embryonic stem cells - cytology - drug effects - metabolism |
5 |
|
embryonic stem cells - drug effects - enzymology - physiology |
5 |
|
endothelial cells - cytology |
5 |
|
endothelial progenitor cells |
5 |
|
genome - genetics |
5 |
|
glycogen storage disease type iib |
5 |
|
hematopoietic stem cells - cytology |
5 |
|
human embryonic stem cells |
5 |
|
lmna |
5 |
|
mus |
5 |
|
myocytes, cardiac - drug effects - enzymology - physiology |
5 |
|
species index: animalia |
5 |
|
triiodothyronine - pharmacology |
5 |
|
x-linked vacuolar cardiomyopathy and myopathy |
5 |
|
biological evolution |
4 |
|
cardiotonic agents - pharmacology |
4 |
|
cardiovascular diseases |
4 |
|
cell hypoxia |
4 |
|
cell therapy |
4 |
|
chronic periodontitis |
4 |
|
chronic periodontitis - metabolism - pathology |
4 |
|
dcm-associated mutations |
4 |
|
endothelial cells - metabolism - pathology |
4 |
|
epithelial cells - metabolism - pathology |
4 |
|
epithelial-mesenchymal transition |
4 |
|
familial dilated cardiomyopathy |
4 |
|
gene expression - drug effects |
4 |
|
hypoxia-inducible factor 1-α subunit |
4 |
|
intracellular signaling peptides and proteins - genetics |
4 |
|
ipsc-induced hepatocytes |
4 |
|
ipscs-derived cardiomyocyte-based disease model |
4 |
|
ipscs-derived cerebral cortical neurons |
4 |
|
lamin a/c |
4 |
|
lamin a/c cardiomyopathy |
4 |
|
lamp2 deficiency |
4 |
|
lysosomal membrane permeabilization |
4 |
|
mitogen-activated protein kinase 1 - metabolism |
4 |
|
mitogen-activated protein kinase 3 - metabolism |
4 |
|
myocytes, cardiac - cytology - drug effects - metabolism |
4 |
|
neuropeptides - genetics |
4 |
|
nonsense mutation |
4 |
|
ouabain |
4 |
|
ouabain - pharmacology |
4 |
|
oxidative stress-induced apoptosis |
4 |
|
patient-specific-induced pluripotent stem cells |
4 |
|
ptc124 |
4 |
|
receptors, g-protein-coupled - genetics |
4 |
|
receptors, gastrointestinal hormone - genetics |
4 |
|
regenerative medicine |
4 |
|
stem cell model |
4 |
|
transgenic mice model |
4 |
|
translational read through |
4 |
|
tumor necrosis factor-alpha |
4 |
|
vascular endothelial growth factor a |
4 |
|
aneuploidy |
3 |
|
cardiovascular disease |
3 |
|
carotid body |
3 |
|
caveolin-1 |
3 |
|
chromosome disorders - genetics - metabolism - physiopathology |
3 |
|
gene expression |
3 |
|
gene transfer techniques |
3 |
|
hypertrophic cardiomyopathy |
3 |
|
induced pluripotent stem cell |
3 |
|
induced pluripotent stem cells - cytology - metabolism |
3 |
|
intermittent hypoxia |
3 |
|
intrinsic cardiac abnormality |
3 |
|
kidney tubules - cytology |
3 |
|
mecp2 mutation |
3 |
|
neuroblastoma cells |
3 |
|
nitric oxide |
3 |
|
nitric oxide synthases |
3 |
|
oxidative stress |
3 |
|
proinflammatory cytokines |
3 |
|
rett syndrome |
3 |
|
sleep apnea |
3 |
|
urine - cytology |
3 |
|
wnt/β-catenin signaling pathway |
3 |
|
alzheimer's disease |
2 |
|
amyloid beta-peptides - metabolism |
2 |
|
anoxia - drug therapy - metabolism - pathology |
2 |
|
aspartic acid endopeptidases |
2 |
|
atherosclerosis |
2 |
|
beta-site app cleavage enzyme |
2 |
|
cardioprotection |
2 |
|
cholesterol |
2 |
|
chronic intermittent hypoxia |
2 |
|
congestive cardiomyopathy |
2 |
|
disease model |
2 |
|
disease modelling |
2 |
|
drug screening |
2 |
|
glycoproteins. |
2 |
|
high-density lipoproteins |
2 |
|
hippocampus - drug effects - metabolism - pathology |
2 |
|
intracellular calcium |
2 |
|
melatonin |
2 |
|
melatonin - pharmacology - therapeutic use |
2 |
|
patient-specific induced pluripotent stem cells |
2 |
|
protein-protein interactions. |
2 |
|
x-linked cardiomyopathy |
2 |
|
β-amyloid |
2 |
|
β-amyloid precursor protein |
2 |
